Emerging therapeutic targets for cerebral edema

References

• Jha RM, Kochanek PM, Simard JM. Pathophysiology and treatment of cerebral edema in traumatic brain injury. Neuropharmacology. 2019;145:230–246.
   PubMed Web of Science ®Google Scholar
• Stokum JA, Gerzanich V, Sheth KN, et al. Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies. Annu Rev Pharmacol Toxicol. 2020 Jan;60(1):291–309.
   PubMed Web of Science ®Google Scholar
• Robert SM, Reeves BC, Alper SL, et al. New drugs on the horizon for cerebral edema: what’s in the clinical development pipeline? Expert Opin Investig Drugs. 2020 Oct;29(10):1099–1105.
   PubMed Web of Science ®Google Scholar
• Battey TWK, Karki M, Singhal AB, et al. Brain edema predicts outcome after nonlacunar ischemic stroke. Stroke. 2014 Dec;45:3643–3648.
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Kemmotsu O, Kitami K, et al. Acute brain swelling after out-of-hospital cardiac arrest: pathogenesis and outcome. Crit Care Med. 1993 Jan;21(1):104–110.
   PubMed Web of Science ®Google Scholar
• Arima H, Wang JG, Huang Y, et al. INTERACT Investigators. Significance of perihematomal edema in acute intracerebral hemorrhage: the INTERACT trial. Neurology. 2009 Dec;73:1963–1968.
   PubMed Web of Science ®Google Scholar
• Wu C-X, Lin G-S, Lin Z-X, et al. Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma. World J Surg Oncol. 2015 Mar;13:97.
   PubMed Web of Science ®Google Scholar
• Rm J, Pm K. A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis? Curr Neurol Neurosci Rep. 2018 Nov;18:105.
   PubMed Web of Science ®Google Scholar
• Zusman BE, Kochanek PM, Jha RM. Cerebral edema in traumatic brain injury: a historical framework for current therapy. Curr Treat Options Neurol. 2020 Mar;22:9.
   PubMed Web of Science ®Google Scholar
• Cooper DJ, Rosenfeld JV, Murray L, et al. DECRA Trial Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med. 2011 Apr;364(16):1493–1502.
   PubMed Web of Science ®Google Scholar
• Shutter LA, Timmons SD. Intracranial Pressure Rescued by Decompressive Surgery after Traumatic Brain Injury. N Engl J Med. 2016 Sep;375(12):1183–1184.
   PubMed Web of Science ®Google Scholar
• Hutchinson PJ, Kolias AG, Timofeev IS, et al. RESCUEicp Trial Collaborators. Trial of decompressive craniectomy for traumatic intracranial hypertension. N Engl J Med. 2016 Sep;375(12):1119–1130.
   PubMed Web of Science ®Google Scholar
• Juttler E, Schwab S, Schmiedek P, et al. the DESTINY Study Group for. Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): A Randomized, Controlled Trial. Stroke. 2007 Aug;38(9):2518–2525.
   PubMed Web of Science ®Google Scholar
• Vahedi K, Hofmeijer J, Juettler E, et al. DECIMAL, DESTINY, and HAMLET investigators. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007 Mar;6(3):215–222.
   PubMed Web of Science ®Google Scholar
• Jüttler E, Unterberg A, Woitzik J, et al. DESTINY II Investigators. Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med. 2014 Mar;370(12):1091–1100.
   PubMed Web of Science ®Google Scholar
• Hofmeijer J, Kappelle LJ, Algra A, et al. HAMLET investigators. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol. 2009 Apr;8(4):326–333.
   PubMed Web of Science ®Google Scholar
• Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral edema. J Cereb Blood Flow Metab. 2016 Mar;36(3):513–538.
   PubMed Web of Science ®Google Scholar
• Simard JM, Kent TA, Chen M, et al. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007 Mar;6(3):258–268.
   PubMed Web of Science ®Google Scholar
• Simon DW, McGeachy MJ, Bayır H, et al. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol. 2017 Feb;13(3):171–191.
   PubMed Web of Science ®Google Scholar
• Yang -Q-Q, Zhou J-W. Neuroinflammation in the central nervous system: Symphony of glial cells. Glia. 2019;67(6):1017–1035.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Schafer D, Vincent A, et al. Neuroinflammation: ways in which the immune system affects the brain. Neurotherapeutics. 2015 Oct;12(4):896–909.
   PubMed Web of Science ®Google Scholar
• Sulhan S, Lyon KA, Shapiro LA, et al. Neuroinflammation and blood-brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets. J Neurosci Res. 2020;98(1):19–28.
   PubMed Web of Science ®Google Scholar
• Hamann S, Herrera-Perez JJ, Zeuthen T, et al. Cotransport of water by the Na+-K+-2Cl(-) cotransporter NKCC1 in mammalian epithelial cells. J. Physiol. (Lond.). 2010 Nov;588(21):4089–4101. https://doi.org/10.1113/jphysiol.2010.194738
   Google Scholar
• Su G, Kintner DB, Sun D. Contribution of Na(+)-K(+)-Cl(−)cotransporter to high-[K(+)](o)- induced swelling and EAA release in astrocytes. Am J Physiol Cell Physiol. 2002 May;282(5):C1136–46.
   PubMed Web of Science ®Google Scholar
• Su G, Kintner DB, Flagella M, et al. Astrocytes from Na(+)-K(+)-Cl(-) cotransporter-null mice exhibit absence of swelling and decrease in EAA release. Am J Physiol Cell Physiol. 2002 May;282(5):C1147–60.
   PubMed Web of Science ®Google Scholar
• Hansson E, Muyderman H, Leonova J, et al. Astroglia and glutamate in physiology and pathology: aspects on glutamate transport, glutamate-induced cell swelling and gap-junction communication. Neurochem Int. 2000 Sep;37(2–3):317–329.
   PubMed Web of Science ®Google Scholar
• Haugeto O, Ullensvang K, Levy LM, et al. Brain glutamate transporter proteins form homomultimers. J Biol Chem. 1996 Nov;271(44):27715–27722.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Watase K, Manabe T, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science. 1997 Jun;276(5319):1699–1702.
   PubMed Web of Science ®Google Scholar
• Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008 Oct;205(11):2473–2481.
   PubMed Web of Science ®Google Scholar
• Bender AS, Schousboe A, Reichelt W, et al. Ionic mechanisms in glutamate-induced astrocyte swelling: role of K+ influx. J Neurosci Res. 1998 May;52(3):307–321.
   PubMed Web of Science ®Google Scholar
• Illarionova NB, Gunnarson E, Li Y, et al. Functional and molecular interactions between aquaporins and Na,K-ATPase. Neuroscience. 2010 Jul;168(4):915–925.
   PubMed Web of Science ®Google Scholar
• Douglas RM, Schmitt BM, Xia Y, et al. Sodium-hydrogen exchangers and sodium-bicarbonate co-transporters: ontogeny of protein expression in the rat brain. Neuroscience. 2001;102(1):217–228.
   PubMed Web of Science ®Google Scholar
• Jakubovicz DE, Klip A. Lactic acid-induced swelling in C6 glial cells via Na+/H+ exchange. Brain Res. 1989 Apr;485(2):215–224.
   PubMed Web of Science ®Google Scholar
• Kintner DB, Su G, Lenart B, et al. Increased tolerance to oxygen and glucose deprivation in astrocytes from Na(+)/H(+) exchanger isoform 1 null mice. Am J Physiol Cell Physiol. 2004 Jul;287(1):C12–21.
   PubMed Web of Science ®Google Scholar
• Kitayama J, Kitazono T, Yao H, et al. Inhibition of Na+/H+ exchanger reduces infarct volume of focal cerebral ischemia in rats. Brain Res. 2001 Dec;922(2):223–228.
   PubMed Web of Science ®Google Scholar
• Bevensee MO, Weed RA, Boron WF. Intracellular pH regulation in cultured astrocytes from rat hippocampus. I. Role Of HCO3-. J. Gen. Physiol. 1997 Oct;110(4):453–465. https://doi.org/10.1085/jgp.110.4.453
   Google Scholar
• Jayakumar AR, Valdes V, Tong XY, et al. Sulfonylurea receptor 1 contributes to the astrocyte swelling and brain edema in acute liver failure. Transl Stroke Res. 2014 Feb;5(1):28–37.
   PubMed Web of Science ®Google Scholar
• Jayakumar AR, Tong XY, Ruiz-Cordero R, et al. Activation of NF-κB mediates astrocyte swelling and brain edema in traumatic brain injury. J Neurotrauma. 2014 Jul;31(14):1249–1257.
   PubMed Web of Science ®Google Scholar
• Jayakumar AR, Panickar KS, Curtis KM, et al. Na-K-Cl cotransporter-1 in the mechanism of cell swelling in cultured astrocytes after fluid percussion injury. J Neurochem. 2011 May;117(3):437–448.
   PubMed Web of Science ®Google Scholar
• Jayakumar AR, Liu M, Moriyama M, et al. Na-K-Cl Cotransporter-1 in the mechanism of ammonia-induced astrocyte swelling. J Biol Chem. 2008 Dec;283(49):33874–33882.
   PubMed Web of Science ®Google Scholar
• Sevick RJ, Kanda F, Mintorovitch J, et al. Cytotoxic brain edema: assessment with diffusion-weighted MR imaging. Radiology. 1992 Dec;185(3):687–690.
   PubMed Web of Science ®Google Scholar
• Corrigan F, Mander KA, Leonard AV, et al. Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation. J Neuroinflammation. 2016 Oct;13(1):264.
   PubMed Web of Science ®Google Scholar
• Song L, Pachter JS. Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc Res. 2004 Jan;67(1):78–89.
   PubMed Web of Science ®Google Scholar
• Yamagata K, Tagami M, Takenaga F, et al. Hypoxia-induced changes in tight junction permeability of brain capillary endothelial cells are associated with IL-1beta and nitric oxide. Neurobiol Dis. 2004 Dec;17(3):491–499.
   PubMed Web of Science ®Google Scholar
• Nag S, Kapadia A, Stewart DJ. Review: molecular pathogenesis of blood-brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol. 2011 Feb;37(1):3–23.
   PubMed Web of Science ®Google Scholar
• Winkler EA, Minter D, Yue JK, et al. Cerebral edema in traumatic brain injury: pathophysiology and prospective therapeutic targets. Neurosurg Clin N Am. 2016 Oct;27(4):473–488.
   PubMed Web of Science ®Google Scholar
• Yang C, Hawkins KE, Doré S, et al. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am J Physiol Cell Physiol. 2019 Feb;316(2):C135–C153.
   PubMed Web of Science ®Google Scholar
• Keep RF, Andjelkovic AV, Xiang J, et al. Brain endothelial cell junctions after cerebral hemorrhage: Changes, mechanisms and therapeutic targets. J Cereb Blood Flow Metab. 2018 May;38(8):1255–1275.
   PubMed Web of Science ®Google Scholar
• Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus. 2007 May;22(5):E4.
   PubMedGoogle Scholar
• Wang W, Dentler WL, Borchardt RT. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H434–40.
   PubMed Web of Science ®Google Scholar
• Mankertz J, Tavalali S, Schmitz H, et al. Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J Cell Sci. 2000 Jun;113(Pt 11):2085–2090.
   PubMed Web of Science ®Google Scholar
• Fischer S, Wobben M, Marti HH, et al. Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc Res. 2002 Jan;63(1):70–80.
   PubMed Web of Science ®Google Scholar
• Schoch HJ, Fischer S, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain. 2002 Nov;125(11):2549–2557.
   PubMed Web of Science ®Google Scholar
• Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. 2007 Apr;27(4):697–709.
   PubMed Web of Science ®Google Scholar
• Yang Y, Rosenberg GA. MMP-mediated disruption of claudin-5 in the blood-brain barrier of rat brain after cerebral ischemia. Methods Mol Biol. 2011;762:333–345.
   PubMedGoogle Scholar
• Xing G, Zhao T, Zhang X, et al. Astrocytic Sonic Hedgehog Alleviates Intracerebral Hemorrhagic Brain Injury via Modulation of Blood-Brain Barrier Integrity. Front. Cell Neurosci. 2020 Dec;14:575690.
   PubMed Web of Science ®Google Scholar
• Brilha S, Ong CWM, Weksler B, et al. Matrix metalloproteinase-9 activity and a downregulated Hedgehog pathway impair blood-brain barrier function in an in vitro model of CNS tuberculosis. Sci Rep. 2017 Nov;7:16031.
   PubMed Web of Science ®Google Scholar
• Liu S, Chang L, Wei C. The sonic hedgehog pathway mediates Tongxinluo capsule-induced protection against blood-brain barrier disruption after ischaemic stroke in mice. Basic Clin Pharmacol Toxicol. 2019 Jun;124:660–669.
   PubMed Web of Science ®Google Scholar
• Michinaga S, Inoue A, Sonoda K, et al. Down-regulation of Astrocytic Sonic Hedgehog by Activation of Endothelin ETB Receptors: Involvement in Traumatic Brain Injury-induced Disruption of Blood Brain Barrier in a Mouse Model. Neurochem Int. 2021;146 ;105042.
   PubMed Web of Science ®Google Scholar
• Chechneva OV, Mayrhofer F, Daugherty DJ, et al. A Smoothened receptor agonist is neuroprotective and promotes regeneration after ischemic brain injury. Cell Death Dis. 2014 Oct;5:e1481.
   PubMed Web of Science ®Google Scholar
• Xia Y, He Q, Li Y, et al. Recombinant human sonic hedgehog protein regulates the expression of ZO-1 and occludin by activating angiopoietin-1 in stroke damage. PLoS One. 2013 Jul;8:e68891.
   PubMed Web of Science ®Google Scholar
• Alvarez JI, Dodelet-Devillers A, Kebir H, et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science. 2011 Dec;334:1727–1731.
   PubMed Web of Science ®Google Scholar
• Manaenko A, Fathali N, Khatibi NH, et al. Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury. Neurochem Int. 2011 Mar;58:542–548.
   PubMed Web of Science ®Google Scholar
• Yi HJ, Lee JE, Lee DH, et al. The role of NLRP3 in traumatic brain injury and its regulation by pioglitazone. J Neurosurg. 2019 Sep;1–9.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen H, Jin J, et al. Inhibition of the NLRP3 inflammasome reduces brain edema and regulates the distribution of aquaporin-4 after cerebral ischaemia-reperfusion. Life Sci. 2020 Jun;251:117638.
   PubMed Web of Science ®Google Scholar
• Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012 Aug;4:147ra111.
   PubMed Web of Science ®Google Scholar
• Mestre H, Mori Y, Nedergaard M. The brain’s glymphatic system: current controversies. Trends Neurosci. 2020 May;43:458–466.
   PubMed Web of Science ®Google Scholar
• Mestre H, Du T, Sweeney AM, et al. Cerebrospinal fluid influx drives acute ischemic tissue swelling. Science. 2020Mar;367.
   PubMed Web of Science ®Google Scholar
• Ji C, Yu X, Xu W, et al. The role of glymphatic system in the cerebral edema formation after ischemic stroke. Exp Neurol. 2021 Mar;113685.
   PubMed Web of Science ®Google Scholar
• Liu E, Sun L, Zhang Y, et al. Aquaporin4 Knockout Aggravates Early Brain Injury Following Subarachnoid Hemorrhage Through Impairment of the Glymphatic System in Rat Brain. Acta Neurochir Suppl. 2020;127:59–64.
   PubMedGoogle Scholar
• Christensen J, Wright DK, Yamakawa GR, et al. Repetitive mild traumatic brain injury alters glymphatic clearance rates in limbic structures of adolescent female rats. Sci Rep. 2020 Apr;10:6254.
   PubMed Web of Science ®Google Scholar
• Pu T, Zou W, Feng W, et al. Persistent malfunction of glymphatic and meningeal lymphatic drainage in a mouse model of subarachnoid hemorrhage. Exp Neurobiol. 2019 Feb;28:104–118.
   PubMed Web of Science ®Google Scholar
• Liu E, Peng X, Ma H, et al. The Involvement of Aquaporin-4 in the Interstitial Fluid Drainage Impairment Following Subarachnoid Hemorrhage. Front Aging Neurosci. 2020;12:611494.
   PubMed Web of Science ®Google Scholar
• Fang Y, Shi H, Ren R, et al. Pituitary Adenylate Cyclase-Activating Polypeptide Attenuates Brain Edema by Protecting Blood-Brain Barrier and Glymphatic System After Subarachnoid Hemorrhage in Rats. Neurotherapeutics. 2020 Sep;17:1954–1972.
   PubMed Web of Science ®Google Scholar
• Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015 Jun;212:991–999.
   PubMed Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015 Jul;523:337–341.
   PubMed Web of Science ®Google Scholar
• Chen J, He J, Ni R, et al. Cerebrovascular Injuries Induce Lymphatic Invasion into Brain Parenchyma to Guide Vascular Regeneration in Zebrafish. Dev Cell. 2019 Jun;49:697–710.e5.
   PubMed Web of Science ®Google Scholar
• Wojciechowski S, Virenque A, Vihma M, et al. Developmental Dysfunction of the Central Nervous System Lymphatics Modulates the Adaptive Neuro-Immune Response in the Perilesional Cortex in a Mouse Model of Traumatic Brain Injury. Front Immunol. 2020;11:559810.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang L, Xu H, et al. Meningeal lymphatics clear erythrocytes that arise from subarachnoid hemorrhage. Nat Commun. 2020 Jun;11:3159.
   PubMed Web of Science ®Google Scholar
• Ma Q, Schlegel F, Bachmann SB, et al. Lymphatic outflow of cerebrospinal fluid is reduced in glioma. Sci Rep. 2019 Oct;9:14815.
   PubMed Web of Science ®Google Scholar
• Clément T, Rodriguez-Grande B, Badaut J. Aquaporins in brain edema. J Neurosci Res. 2020;98:9–18.
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013 Apr;14:265–277.
   PubMed Web of Science ®Google Scholar
• Tomás-Camardiel M, Venero JL, de Pablos RM, et al. In vivo expression of aquaporin-4 by reactive microglia. J Neurochem. 2004 Nov;91:891–899.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Migliati E, Amiry-Moghaddam M, et al. Osmotherapy With Hypertonic Saline Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4. Crit Care Med. 2016 Aug;44:e702–10.
   PubMed Web of Science ®Google Scholar
• Stokum JA, Kwon MS, Woo SK, et al. SUR1-TRPM4 and AQP4 form a heteromultimeric complex that amplifies ion/water osmotic coupling and drives astrocyte swelling. Glia. 2018;66:108–125.
   PubMed Web of Science ®Google Scholar
• Xu X, Yin D, Ren H, et al. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury. Neurobiol Dis. 2018 May;117:15–27.
   PubMed Web of Science ®Google Scholar
• Manley GT, Fujimura M, Ma T, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med. 2000 Feb;6:159–163.
   PubMed Web of Science ®Google Scholar
• Taya K, Marmarou CR, Okuno K, et al. Effect of secondary insults upon aquaporin-4 water channels following experimental cortical contusion in rats. J Neurotrauma. 2010 Jan;27:229–239.
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Manley GT, Krishna S, et al. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004 Aug;18:1291–1293.
   PubMed Web of Science ®Google Scholar
• Wallisch JS, Janesko-Feldman K, Alexander H, et al. The aquaporin-4 inhibitor AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest. Pediatr Res. 2019 Mar;85:511–517.
   PubMed Web of Science ®Google Scholar
• Wallisch J, Jha R, Vagni V, et al. Effect of the novel aquaporin-4 antagonist AER-271 in combined TBI plus hemorrhagic shock in mice. Crit Care Med. 2015 Dec;43:6–7.
   Web of Science ®Google Scholar
• Chen J-Q, Zhang -C-C, Jiang S-N, et al. Effects of aquaporin 4 knockdown on brain edema of the uninjured side after traumatic brain injury in rats. Med Sci Monit. 2016 Dec;22:4809–4819.
   PubMed Web of Science ®Google Scholar
• Fukuda AM, Adami A, Pop V, et al. Posttraumatic reduction of edema with aquaporin-4 RNA interference improves acute and chronic functional recovery. J Cereb Blood Flow Metab. 2013 Oct;33:1621–1632.
   PubMed Web of Science ®Google Scholar
• Higashida T, Kreipke CW, Rafols JA, et al. The role of hypoxia-inducible factor-1α, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury. J Neurosurg. 2011 Jan;114:92–101.
   PubMed Web of Science ®Google Scholar
• Kiening KL, van Landeghem FKH, Schreiber S, et al. Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats. Neurosci Lett. 2002 May;324:105–108.
   PubMed Web of Science ®Google Scholar
• Ren Z, Iliff JJ, Yang L, et al. “Hit & Run” model of closed-skull traumatic brain injury (TBI) reveals complex patterns of post-traumatic AQP4 dysregulation. J Cereb Blood Flow Metab. 2013 Jun;33:834–845.
   PubMed Web of Science ®Google Scholar
• Yao X, Uchida K, Papadopoulos MC, et al. Mildly Reduced Brain Swelling and Improved Neurological Outcome in Aquaporin-4 Knockout Mice following Controlled Cortical Impact Brain Injury. J Neurotrauma. 2015 Oct;32:1458–1464.
   PubMed Web of Science ®Google Scholar
• Hu H, Yao H, Zhang W, et al. Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors. J Zhejiang Univ Sci B. 2005 Jan;6:33–37.
   PubMedGoogle Scholar
• Lo Pizzo M, Schiera G, Di Liegro I, et al. Aquaporin-4 distribution in control and stressed astrocytes in culture and in the cerebrospinal fluid of patients with traumatic brain injuries. Neurol Sci. 2013 Aug;34:1309–1314.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Paterakis K, Tsivgoulis G, et al. AQP4 tag single nucleotide polymorphisms in patients with traumatic brain injury. J Neurotrauma. 2014 Dec;31(23):1920–1926.
   PubMed Web of Science ®Google Scholar
• Rotondo F, Butz H, Syro LV, et al. Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. Pituitary. 2016 Aug;19(4):345–355.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV, Hyman S, McComb JG, et al. Kinetics of arginine-vasopressin uptake at the blood-brain barrier. Biochim Biophys Acta. 1990 Jun;1025(2):191–198.
   PubMed Web of Science ®Google Scholar
• Chodobski A, Loh YP, Corsetti S, et al. The presence of arginine vasopressin and its mRNA in rat choroid plexus epithelium. Brain Res. Mol. Brain Res. 1997 Aug;48(1):67–72. https://doi.org/10.1016/S0169-328X(97)00079-X
   PubMedGoogle Scholar
• Szmydynger-Chodobska J, Zink BJ, Chodobski A. Multiple sites of vasopressin synthesis in the injured brain. J Cereb Blood Flow Metab. 2011 Jan;31(1):47–51.
   PubMed Web of Science ®Google Scholar
• Buijs RM, Swaab DF, Dogterom J, et al. Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Cell Tissue Res. 1978 Jan;186(3):423–433.
   PubMed Web of Science ®Google Scholar
• Raichle ME, Grubb RL. Regulation of brain water permeability by centrally-released vasopressin. Brain Res. 1978 Mar;143(1):191–194.
   PubMed Web of Science ®Google Scholar
• Sarfaraz D, Fraser CL. Effects of arginine vasopressin on cell volume regulation in brain astrocyte in culture. Am J Physiol. 1999;276(3):E596–601.
   PubMedGoogle Scholar
• Latzkovits L, Cserr HF, Park JT, et al. Effects of arginine vasopressin and atriopeptin on glial cell volume measured as 3-MG space. Am J Physiol. 1993 Mar;264(3):C603–8.
   PubMed Web of Science ®Google Scholar
• Faraci FM, Mayhan WG, Heistad DD. Effect of vasopressin on production of cerebrospinal fluid: possible role of vasopressin (V1)-receptors. Am J Physiol. 1990 Jan;258(1 Pt 2):R94–8.
   PubMed Web of Science ®Google Scholar
• Seckl JR, Lightman SL. Intracerebroventricular vasopressin reduces CSF absorption rate in the conscious goat. Exp Brain Res. 1991;84(1):173–176.
   PubMed Web of Science ®Google Scholar
• Filippidis AS, Liang X, Wang W, et al. Real-time monitoring of changes in brain extracellular sodium and potassium concentrations and intracranial pressure after selective vasopressin-1a receptor inhibition following focal traumatic brain injury in rats. J Neurotrauma. 2014 Jul;31(14):1258–1267.
   PubMed Web of Science ®Google Scholar
• Liu X, Nakayama S, Amiry-Moghaddam M, et al. Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke. Neurocrit Care. 2010 Feb;12(1):124–131.
   PubMed Web of Science ®Google Scholar
• Krieg SM, Trabold R, Plesnila N. Time-Dependent Effects of Arginine-Vasopressin V1 Receptor Inhibition on Secondary Brain Damage after Traumatic Brain Injury. J Neurotrauma. 2017 Apr;34(7):1329–1336.
   PubMed Web of Science ®Google Scholar
• Kleindienst A, Dunbar JG, Glisson R, et al. The role of vasopressin V1A receptors in cytotoxic brain edema formation following brain injury. Acta Neurochir (Wien). 2013 Jan;155(1):151–164.
   PubMed Web of Science ®Google Scholar
• Pascale CL, Szmydynger-Chodobska J, Sarri JE, et al. Traumatic brain injury results in a concomitant increase in neocortical expression of vasopressin and its V1a receptor. J Physiol Pharmacol. 2006 Nov;57(Suppl 11):161–167.
   PubMed Web of Science ®Google Scholar
• Rauen K, Trabold R, Brem C, et al. Arginine Vasopressin V1a Receptor-Deficient Mice Have Reduced Brain Edema and Secondary Brain Damage following Traumatic Brain Injury. J Neurotrauma. 2013 Aug;30(16):1442–1448.
   PubMed Web of Science ®Google Scholar
• Vakili A, Kataoka H, Plesnila N. Role of Arginine Vasopressin V1 and V2 Receptors for Brain Damage After Transient Focal Cerebral Ischemia. J Cereb Blood Flow Metab. 2005 Aug;25(8):1012–1019.
   PubMed Web of Science ®Google Scholar
• Krieg SM, Sonanini S, Plesnila N, et al. Effect of Small Molecule Vasopressin V1a and V2 Receptor Antagonists on Brain Edema Formation and Secondary Brain Damage following Traumatic Brain Injury in Mice. J Neurotrauma. 2015 Feb;32(4):221–227
   PubMed Web of Science ®Google Scholar
• Marmarou CR, Liang X, Abidi NH, et al. Selective vasopressin-1a receptor antagonist prevents brain edema, reduces astrocytic cell swelling and GFAP, V1aR and AQP4 expression after focal traumatic brain injury. Brain Res. 2014 Sep;1581:89–102.
   PubMed Web of Science ®Google Scholar
• Dhar R, Murphy-Human T. A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury. Neurocrit Care. 2011 Feb;14(1):97–102.
   PubMed Web of Science ®Google Scholar
• Hedna VS, Bidari S, Gubernick D, et al. Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: a case report and review of the literature. BMC Neurol. 2014 Nov;14(1):213.
   PubMed Web of Science ®Google Scholar
• Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care. 2009 Jan;11(1):14–19.
   PubMed Web of Science ®Google Scholar
• Corry JJ, Asaithambi G, Shaik AM, et al. Conivaptan for the reduction of cerebral edema in intracerebral hemorrhage: A safety and tolerability study. Clin Drug Investig. 2020 May;40(5):503–509.
   PubMed Web of Science ®Google Scholar
• Yang C, Yang Y, DeMars KM, et al Genetic Deletion or Pharmacological Inhibition of Cyclooxygenase-2 Reduces Blood-Brain Barrier Damage in Experimental Ischemic Stroke. Front Neurol. 2020 Aug;11:887.
   PubMed Web of Science ®Google Scholar
• Wang J, Doré S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2007 May;27(5):894–908.
   PubMed Web of Science ®Google Scholar
• Gong C, Ennis SR, Hoff JT, et al. Inducible cyclooxygenase-2 expression after experimental intracerebral hemorrhage. Brain Res. 2001 May;901(1–2):38–46.
   PubMed Web of Science ®Google Scholar
• Strauss KI. Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain. Brain Behav Immun. 2008 Mar;22(3):285–298.
   PubMed Web of Science ®Google Scholar
• Liu H, Rose ME, Miller TM, et al. COX2-derived primary and cyclopentenone prostaglandins are increased after asphyxial cardiac arrest. Brain Res. 2013 Jun;1519:71–77.
   PubMed Web of Science ®Google Scholar
• Wu T, Wu H, Wang J, et al. Expression and cellular localization of cyclooxygenases and prostaglandin E synthases in the hemorrhagic brain. J Neuroinflammation. 2011 Mar;8(1):22.
   PubMed Web of Science ®Google Scholar
• Zhang H-B, Tu X-K, Chen Q, et al. Propofol Reduces Inflammatory Brain Injury after Subarachnoid Hemorrhage: Involvement of PI3K/Akt Pathway. J Stroke Cerebrovasc Dis. 2019 Dec;28(12):104375.
   PubMed Web of Science ®Google Scholar
• Cernak I, O’Connor C, Vink R. Activation of cyclo-oxygenase-2 contributes to motor and cognitive dysfunction following diffuse traumatic brain injury in rats. Clin Exp Pharmacol Physiol. 2001 Nov;28(11):922–925.
   PubMed Web of Science ®Google Scholar
• Strauss KI, Barbe MF, Marshall RM, et al. Prolonged cyclooxygenase-2 induction in neurons and glia following traumatic brain injury in the rat. J Neurotrauma. 2000 Aug;17(8):695–711.
   PubMed Web of Science ®Google Scholar
• Munakata A, Naraoka M, Katagai T, et al. Role of Cyclooxygenase-2 in Relation to Nitric Oxide and Endothelin-1 on Pathogenesis of Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbit. Transl Stroke Res. 2016 Apr;7(3):220–227.
   PubMed Web of Science ®Google Scholar
• Tran Dinh YR, Jomaa A, Callebert J, et al. Overexpression of cyclooxygenase-2 in rabbit basilar artery endothelial cells after subarachnoid hemorrhage. Neurosurgery. 2001 Mar;48(3):626–633. discussion 633.
   PubMed Web of Science ®Google Scholar
• Dash PK, Mach SA, Moore AN. Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury. J Neurotrauma. 2000 Jan;17(1):69–81.
   PubMed Web of Science ®Google Scholar
• Dehlaghi Jadid K, Davidsson J, Lidin E, et al. COX-2 Inhibition by Diclofenac Is Associated With Decreased Apoptosis and Lesion Area After Experimental Focal Penetrating Traumatic Brain Injury in Rats. Front Neurol. 2019 Jul;10:811.
   PubMed Web of Science ®Google Scholar
• Cernak I, O’Connor C, Vink R. Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats. Exp Brain Res. 2002 Nov;147(2):193–199.
   PubMed Web of Science ®Google Scholar
• Ayer R, Jadhav V, Sugawara T, et al. The neuroprotective effects of cyclooxygenase-2 inhibition in a mouse model of aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl. 2011;111:145–149.
   PubMedGoogle Scholar
• Sinn D-I, Lee S-T, Chu K, et al. Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. Neurosci Lett. 2007 Jan;411(3):238–242.
   PubMed Web of Science ®Google Scholar
• Chu K, Jeong S-W, Jung K-H, et al. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab. 2004 Aug;24(8):926–933.
   PubMed Web of Science ®Google Scholar
• Santos-Galdiano M, Pérez-Rodríguez D, Anuncibay-Soto B, et al. Celecoxib Treatment Improves Neurologic Deficit and Reduces Selective Neuronal Loss and Glial Response in Rats after Transient Middle Cerebral Artery Occlusion. J Pharmacol Exp Ther. 2018 Oct;367(3):528–542.
   PubMed Web of Science ®Google Scholar
• Si D, Li J, Liu J, et al. Progesterone protects blood-brain barrier function and improves neurological outcome following traumatic brain injury in rats. Exp Ther Med. 2014 Sep;8(3):1010–1014.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang J, Si D, et al. Progesterone inhibits the expression of cycloxygenase-2 and interleukin-1β in neonatal rats with hypoxic ischemic brain damage. Int J Neurosci. 2014 Jan;124(1):42–48.
   PubMed Web of Science ®Google Scholar
• Cutler SM, Cekic M, Miller DM, et al. Progesterone improves acute recovery after traumatic brain injury in the aged rat. J Neurotrauma. 2007 Sep;24(9):1475–1486.
   PubMed Web of Science ®Google Scholar
• Si D, Wang H, Wang Q, et al. Progesterone treatment improves cognitive outcome following experimental traumatic brain injury in rats. Neurosci Lett. 2013 Oct;553:18–23.
   PubMed Web of Science ®Google Scholar
• Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000 Feb;40(2):124–132.
   PubMed Web of Science ®Google Scholar
• Park H-K, Lee S-H, Chu K, et al. Effects of celecoxib on volumes of hematoma and edema in patients with primary intracerebral hemorrhage. J Neurol Sci. 2009 Apr;279(1–2):43–46.
   PubMed Web of Science ®Google Scholar
• Lee SH, Park HK, Ryu WS, et al. Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: a multicenter randomized controlled trial. Eur J Neurol. 2013 Aug;20(8):1161–1169.
   PubMed Web of Science ®Google Scholar
• Naseh M, Vatanparast J, Rafati A, et al. The emerging role of FTY720 as a sphingosine 1-phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms. Brain Behav. 2021 May;11(6):e02179.
   PubMed Web of Science ®Google Scholar
• Kraft P, Göb E, Schuhmann MK, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke. 2013 Nov;44(11):3202–3210.
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004 Jan;427(6972):355–360.
   PubMed Web of Science ®Google Scholar
• Pham THM, Okada T, Matloubian M, et al. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity. 2008 Jan;28(1):122–133.
   PubMed Web of Science ®Google Scholar
• Gaire BP, Lee C-H, Sapkota A, et al. Identification of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P1) as a Pathogenic Factor in Transient Focal Cerebral Ischemia. Mol Neurobiol. 2018;55(3):2320–2332.
   PubMed Web of Science ®Google Scholar
• Sapkota A, Gaire BP, Kang M-G, et al. S1P2 contributes to microglial activation and M1 polarization following cerebral ischemia through ERK1/2 and JNK. Sci Rep. 2019 Aug;9(1):12106.
   PubMed Web of Science ®Google Scholar
• Gaire BP, Song M-R, Choi JW. Sphingosine 1-phosphate receptor subtype 3 (S1P3) contributes to brain injury after transient focal cerebral ischemia via modulating microglial activation and their M1 polarization. J Neuroinflammation. 2018 Oct;15(1):284.
   PubMed Web of Science ®Google Scholar
• Li X, Wang M-H, Qin C, et al. Fingolimod suppresses neuronal autophagy through the mTOR/p70S6K pathway and alleviates ischemic brain damage in mice. PLoS One. 2017 Nov;12(11):e0188748.
   PubMed Web of Science ®Google Scholar
• Safarian F, Khallaghi B, Ahmadiani A, et al. Activation of S1P₁ receptor regulates PI3K/Akt/FoxO3a pathway in response to oxidative stress in PC12 cells. J Mol Neurosci. 2015 May;56(1):177–187.
   PubMed Web of Science ®Google Scholar
• Xiang P, Chew WS, Seow WL, et al. The S1P2 receptor regulates blood-brain barrier integrity and leukocyte extravasation with implications for neurodegenerative disease. Neurochem Int. 2021 Jun;146:105018.
   PubMed Web of Science ®Google Scholar
• Wacker BK, Park TS, Gidday JM. Hypoxic preconditioning-induced cerebral ischemic tolerance: role of microvascular sphingosine kinase 2. Stroke. 2009 Oct;40(10):3342–3348.
   PubMed Web of Science ®Google Scholar
• Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. CNS Drugs. 2021 Apr;35(4):385–402.
   PubMed Web of Science ®Google Scholar
• Xu H-L, Pelligrino DA, Paisansathan C, et al. Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage. J Neuroinflammation. 2015 Jan;12(1):16.
   PubMed Web of Science ®Google Scholar
• Tschoe C, Bushnell CD, Duncan PW, et al. Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets. J. Stroke. 2020 Jan;22(1):29–46. DOI:https://doi.org/10.5853/jos.2019.02236
   PubMed Web of Science ®Google Scholar
• Napier J, Rose L, Adeoye O, et al. Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis. Immunopharmacol Immunotoxicol. 2019 Feb;41(1):7–15.
   PubMed Web of Science ®Google Scholar
• Gao C, Qian Y, Huang J, et al. A Three-Day Consecutive Fingolimod Administration Improves Neurological Functions and Modulates Multiple Immune Responses of CCI Mice. Mol Neurobiol. 2017 Dec;54(10):8348–8360.
   PubMed Web of Science ®Google Scholar
• Sun N, Shen Y, Han W, et al. Selective Sphingosine-1-Phosphate Receptor 1 Modulation Attenuates Experimental Intracerebral Hemorrhage. Stroke. 2016 May;47(7):1899–1906.
   PubMed Web of Science ®Google Scholar
• Rolland WB, Lekic T, Krafft PR, et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp Neurol. 2013 Mar;241:45–55.
   PubMed Web of Science ®Google Scholar
• Rolland WB, Manaenko A, Lekic T, et al. FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice. Acta Neurochir Suppl. 2011;111:213–217.
   PubMedGoogle Scholar
• Wang Y, Zhou S, Han Z, et al Fingolimod administration improves neurological functions of mice with subarachnoid hemorrhage. Neurosci Lett. 2020 Sep;736:135250.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ding K, Wang H, et al. Traumatic Brain Injury-Induced Neuronal Apoptosis is Reduced Through Modulation of PI3K and Autophagy Pathways in Mouse by FTY720. Cell Mol. Neurobiol. 2016 Jan;36(1):131–142. https://doi.org/10.1007/s10571-015-0227-1
   PubMed Web of Science ®Google Scholar
• Oshima Y, Tanimoto T, Yuji K, et al. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler. 2019;25(8):1141–1149.
   PubMed Web of Science ®Google Scholar
• Fu Y, Hao J, Zhang N, et al. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 2014 Sep;71(9):1092–1101.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhang N, Ren L, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci USA. 2014 Dec;111(51):18315–18320.
   PubMed Web of Science ®Google Scholar
• Tian D-C, Shi K, Zhu Z, et al. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow. Ann Neurol. 2018 Nov;84(5):717–728.
   PubMed Web of Science ®Google Scholar
• Männer A, Thomas D, Wagner M, et al. Sphingosine 1-phosphate levels in cerebrospinal fluid after subarachnoid hemorrhage. Neurol. Res. Pract. 2020 Nov;2(1):49. https://doi.org/10.1186/s42466-020-00093-x
   PubMedGoogle Scholar
• Chen M, Simard JM. Cell Swelling and a Nonselective Cation Channel Regulated by Internal Ca2+ and ATP in Native Reactive Astrocytes from Adult Rat Brain. J Neurosci. 2001 Sep;21(17):6512–6521.
   PubMed Web of Science ®Google Scholar
• Jha RM, Bell J, Citerio G, et al. Role of sulfonylurea receptor 1 and glibenclamide in traumatic brain injury: A review of the evidence. Int J Mol Sci. 2020 Jan;21.
   Web of Science ®Google Scholar
• Woo SK, Tsymbalyuk N, Tsymbalyuk O, et al. SUR1-TRPM4 channels, not KATP, mediate brain swelling following cerebral ischemia. Neurosci Lett. 2020 Jan;718:134729.
   PubMed Web of Science ®Google Scholar
• Gerzanich V, Stokum JA, Ivanova S, et al. Sulfonylurea receptor 1, transient receptor potential cation channel subfamily M member 4, and kir6.2: rolein hemorrhagic progression of contusion. J Neurotrauma. 2019 Apr;36(7):1060–1079.
   PubMed Web of Science ®Google Scholar
• Simard JM, Chen M, Tarasov KV, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med. 2006 Apr;12(4):433–440. DOI:https://doi.org/10.1038/nm1390.
   PubMed Web of Science ®Google Scholar
• Boggs DH, Simard JM, Steven A, et al. Potential of glyburide to reduce intracerebral edema in brain metastases. Expert Rev Neurother. 2014 Apr;14(4):379–388.
   PubMed Web of Science ®Google Scholar
• Kurland D, Hong C, Aarabi B, et al. Hemorrhagic progression of a contusion after traumatic brain injury: a review. J Neurotrauma. 2012 Jan;29(1):19–31.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Taguchi N, Isaka Y, et al. Glibenclamide and therapeutic hypothermia have comparable effect on attenuating global cerebral edema following experimental cardiac arrest. Neurocrit Care. 2018;29(1):119–127.
   PubMed Web of Science ®Google Scholar
• Jha RM, Mondello S, Bramlett HM, et al. Glibenclamide treatment in traumatic brain injury: operation brain trauma therapy. J Neurotrauma. 2021 Mar;38(5):628–645.
   PubMed Web of Science ®Google Scholar
• Jha RM, Molyneaux BJ, Jackson TC, et al. Glibenclamide Produces Region-Dependent Effects on Cerebral Edema in a Combined Injury Model of Traumatic Brain Injury and Hemorrhagic Shock in Mice. J Neurotrauma. 2018 Sep;35(17):2125–2135.
   PubMed Web of Science ®Google Scholar
• Simard JM, Tsymbalyuk O, Ivanov A, et al. Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. J Clin Invest. 2007 Aug;117(8):2105–2113.
   PubMed Web of Science ®Google Scholar
• Tsymbalyuk O, Gerzanich V, Mumtaz A, et al. SUR1, newly expressed in astrocytes, mediates neuropathic pain in a mouse model of peripheral nerve injury. Mol Pain. 2021 Dec;17:17448069211006604.
   Web of Science ®Google Scholar
• Simard JM, Popovich PG, Tsymbalyuk O, et al. Spinal cord injury with unilateral versus bilateral primary hemorrhage–effects of glibenclamide. Exp Neurol. 2012 Feb;233(2):829–835.
   PubMed Web of Science ®Google Scholar
• Woo SK, Kwon MS, Ivanov A, et al. The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel. J Biol Chem. 2013 Feb;288(5):3655–3667.
   PubMed Web of Science ®Google Scholar
• Simard JM, Woo SK, Norenberg MD, et al. Brief Suppression of Abcc8 Prevents Autodestruction of Spinal Cord After Trauma. Sci Transl Med. 2010 Apr;2(28):28ra29.
   PubMed Web of Science ®Google Scholar
• Makar TK, Gerzanich V, Nimmagadda VKC, et al. Silencing of Abcc8 or inhibition of newly upregulated Sur1-Trpm4 reduce inflammation and disease progression in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2015 Nov;12(1):210.
   PubMed Web of Science ®Google Scholar
• Simard JM, Woo SK, Schwartzbauer GT, et al. Sulfonylurea receptor 1 in central nervous system injury: a focused review. J Cereb Blood Flow Metab. 2012 Sep;32(9):1699–1717.
   PubMed Web of Science ®Google Scholar
• Gerzanich V, Makar TK, Guda PR, et al. Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis. J Neuroinflammation. 2017 Sep;14(1):177.
   PubMed Web of Science ®Google Scholar
• Tata S, Zusman BE, Kochanek PM, et al. Abcc8 (Sulfonylurea Receptor-1) Impact on Brain Atrophy after Traumatic Brain Injury Varies by Sex. J Neurotrauma. 2021 May;38(17):2473–2485.
   PubMed Web of Science ®Google Scholar
• Mehta RI, Tosun C, Ivanova S, et al. Sur1-Trpm4 Cation Channel Expression in Human Cerebral Infarcts. J Neuropathol Exp Neurol. 2015 Aug;74(8):835–849.
   PubMed Web of Science ®Google Scholar
• Nilius B, Prenen J, Tang J, et al. Regulation of the Ca2+ sensitivity of the nonselective cation channel TRPM4. J Biol Chem. 2005 Feb;280(8):6423–6433.
   PubMed Web of Science ®Google Scholar
• Chen M, Dong Y, Simard JM. Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain. J Neurosci. 2003 Sep;23(24):8568–8577.
   PubMed Web of Science ®Google Scholar
• Sheth KN, Elm JJ, Molyneaux BJ, et al. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15(11):1160–1169. DOI:https://doi.org/10.1016/S1474-4422(16)30196-X.
   PubMed Web of Science ®Google Scholar
• Kurland DB, Gerzanich V, Karimy JK, et al. The Sur1-Trpm4 channel regulates NOS2 transcription in TLR4-activated microglia. J Neuroinflammation. 2016 Jun;13(1):130.
   PubMed Web of Science ®Google Scholar
• Gerzanich V, Kwon MS, Woo SK, et al. SUR1-TRPM4 channel activation and phasic secretion of MMP-9 induced by tPA in brain endothelial cells. PLoS One. 2018 Apr;13(4):e0195526.
   PubMed Web of Science ®Google Scholar
• Martínez-Valverde T, Vidal-Jorge M, Martínez-Saez E, et al. Sulfonylurea Receptor 1 in Humans with Post-Traumatic Brain Contusions. J Neurotrauma. 2015 Oct;32(19):1478–1487.
   PubMed Web of Science ®Google Scholar
• Huang K, Gu Y, Hu Y, et al. Glibenclamide improves survival and neurologic outcome after cardiac arrest in rats. Crit Care Med. 2015 Sep;43(9):e341–9.
   PubMed Web of Science ®Google Scholar
• Xu F, Shen G, Su Z, et al. Glibenclamide ameliorates the disrupted blood-brain barrier in experimental intracerebral hemorrhage by inhibiting the activation of NLRP3 inflammasome. Brain Behav. 2019 Mar;9(4):e01254.
   PubMed Web of Science ®Google Scholar
• Stokum JA, Keledjian K, Hayman E, et al. Glibenclamide pretreatment protects against chronic memory dysfunction and glial activation in rat cranial blast traumatic brain injury. Behav Brain Res. 2017 Aug;333:43–53.
   PubMed Web of Science ®Google Scholar
• Zweckberger K, Hackenberg K, Jung CS, et al. Glibenclamide reduces secondary brain damage after experimental traumatic brain injury. Neuroscience. 2014 Jul;272:199–206.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Sastre C, Wolcott Z, et al. Continuous Glibenclamide Prevents Hemorrhagic Transformation in a Rodent Model of Severe Ischemia-Reperfusion. J Stroke Cerebrovasc Dis. 2021 Mar;30(3):105595.
   PubMed Web of Science ®Google Scholar
• Ortega FJ, Jolkkonen J, Mahy N, et al. Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2013 Mar;33(3):356–364.
   PubMed Web of Science ®Google Scholar
• Jiang B, Li L, Chen Q, et al. Role of glibenclamide in brain injury after intracerebral hemorrhage. Transl Stroke Res. 2017;8(2):183–193.
   PubMed Web of Science ®Google Scholar
• Wang X, Chang Y, He Y, et al. Glimepiride and glibenclamide have comparable efficacy in treating acute ischemic stroke in mice. Neuropharmacology. 2020 Jan;162:107845.
   PubMed Web of Science ®Google Scholar
• Zhang G, Lin X, Zhang S, et al. Role of Glibenclamide in Inflammation-Associated Injury. Mediators Inflamm. 2017 Jun;2017:3578702.
   PubMed Web of Science ®Google Scholar
• Z-m X, Yuan F, Y-l L, et al. Glibenclamide Attenuates Blood-Brain Barrier Disruption in Adult Mice after Traumatic Brain Injury. J Neurotrauma. 2017 Feb;34(4):925–933.
   PubMed Web of Science ®Google Scholar
• Simard JM, Tsymbalyuk N, Tsymbalyuk O, et al. Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke. 2010 Mar;41(3):531–537.
   PubMed Web of Science ®Google Scholar
• Thompson EM, Pishko GL, Muldoon LL, et al. Inhibition of SUR1 decreases the vascular permeability of cerebral metastases. Neoplasia. 2013 May;15(5):535–543.
   PubMed Web of Science ®Google Scholar
• Tosun C, Koltz MT, Kurland DB, et al. The protective effect of glibenclamide in a model of hemorrhagic encephalopathy of prematurity. Brain Sci. 2013 Mar;3(3):215–238.
   PubMedGoogle Scholar
• Simard JM, Geng Z, Woo SK, et al. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2009 Feb;29(2):317–330.
   PubMed Web of Science ®Google Scholar
• Tosun C, Kurland DB, Mehta R, et al. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. Stroke. 2013 Dec;44(12):3522–3528.
   PubMed Web of Science ®Google Scholar
• Deng G, Ma C, Zhao H, et al. Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles. Theranostics. 2019 Sep;9(23):6991–7002.
   PubMed Web of Science ®Google Scholar
• Castro L, Noelia M, Vidal-Jorge M, et al. Kir6.2, the Pore-Forming Subunit of ATP-Sensitive K+ Channels, Is Overexpressed in Human Posttraumatic Brain Contusions. J Neurotrauma. 2019 Jan;36(1):165–175.
   PubMed Web of Science ®Google Scholar
• Mehta RI, Ivanova S, Tosun C, et al. Sulfonylurea receptor 1 expression in human cerebral infarcts. J Neuropathol Exp Neurol. 2013 Sep;72(9):871–883.
   PubMed Web of Science ®Google Scholar
• Thompson EM, Halvorson K, McLendon R. Sulfonylurea receptor 1 expression is variable in adult and pediatric brain tumors. Clin Neuropathol. 2018;37(5):221–227.
   PubMed Web of Science ®Google Scholar
• Zusman BE, Kochanek PM, Bell MJ, et al. Cerebrospinal Fluid Sulfonylurea Receptor-1 Is Associated with Intracranial Pressure and Outcome after Pediatric TBI: An Exploratory Analysis of the Cool Kids Trial. J Neurotrauma. 2021 Feb;38(12):1615–1619.
   PubMed Web of Science ®Google Scholar
• Jha RM, Puccio AM, Chou SH-Y, et al. Sulfonylurea Receptor-1: A Novel Biomarker for Cerebral Edema in Severe Traumatic Brain Injury. Crit Care Med. 2017;45(3):e255–e264.
   PubMedGoogle Scholar
• Dundar TT, Abdallah A, Yurtsever I, et al. Serum SUR1 and TRPM4 in patients with subarachnoid hemorrhage. Neurosurg Rev. 2020 Dec;43(6):1595–1603.
   PubMed Web of Science ®Google Scholar
• Jha RM, Desai SM, Zusman BE, et al. Downstream TRPM4 Polymorphisms Are Associated with Intracranial Hypertension and Statistically Interact with ABCC8 Polymorphisms in a Prospective Cohort of Severe Traumatic Brain Injury. J Neurotrauma. 2019 Feb;36(11):1804–1817.
   PubMed Web of Science ®Google Scholar
• Jha RM, Puccio AM, Okonkwo DO, et al. ABCC8 Single Nucleotide Polymorphisms are Associated with Cerebral Edema in Severe TBI. Neurocrit Care. 2017;26(2):213–224.
   PubMed Web of Science ®Google Scholar
• Jha RM, Koleck TA, Puccio AM, et al. Regionally clustered ABCC8 polymorphisms in a prospective cohort predict cerebral oedema and outcome in severe traumatic brain injury. J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1152–1162.
   PubMed Web of Science ®Google Scholar
• Kunte H, Schmidt S, Eliasziw M, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke. 2007 Sep;38(9):2526–2530.
   PubMed Web of Science ®Google Scholar
• Kunte H, Busch MA, Trostdorf K, et al. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol. 2012 Nov;72(5):799–806.
   PubMed Web of Science ®Google Scholar
• Khalili H, Derakhshan N, Niakan A, et al. Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injuries: A Randomized Double-Blind Placebo-Controlled Clinical Trial. World Neurosurg. 2017 May;101:130–136.
   PubMed Web of Science ®Google Scholar
• Zafardoost P, Ghasemi AA, Salehpour F, et al. Evaluation of the effect of glibenclamide in patients with diffuse axonal injury due to moderate to severe head trauma. Trauma Mon. 2016 Nov;21(5):e25113. https://doi.org/10.5812/traumamon.25113
   PubMed Web of Science ®Google Scholar
• Huang K, Hu Y, Wu Y, et al. Exploratory analysis of oral glibenclamide in acute ischemic stroke. Acta Neurol Scand. 2019 Sep;140(3):212–218.
   PubMed Web of Science ®Google Scholar
• Huang K, Ji Z, Wu Y, et al. Safety and efficacy of glibenclamide combined with rtPA in acute cerebral ischemia with occlusion/stenosis of anterior circulation (SE-GRACE): study protocol for a randomized controlled trial. BMC Neurol. 2020 Jun;20(1):239.
   PubMed Web of Science ®Google Scholar
• Minnema AJ, Mehta A, Boling WW, et al. SCING-Spinal Cord Injury Neuroprotection with Glyburide: a pilot, open-label, multicentre, prospective evaluation of oral glyburide in patients with acute traumatic spinal cord injury in the USA. BMJ Open. 2019 Oct;9(10):e031329.
   PubMed Web of Science ®Google Scholar
• Armahizer MJ, Howard AK, Seung H, et al. Risk Factors for Hypoglycemia with the Use of Enteral Glyburide in Neurocritical Care Patients. World Neurosurg. 2021 Mar;147:e63–e68.
   PubMed Web of Science ®Google Scholar
• Vorasayan P, Bevers MB, Beslow LA, et al. Intravenous glibenclamide reduces lesional water uptake in large hemispheric infarction. Stroke. 2019 Sep;50(11):3021–3027.
   PubMed Web of Science ®Google Scholar
• Sheth KN, Petersen NH, Cheung K, et al. Long-Term Outcomes in Patients Aged ≤70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis. Stroke. 2018 May;49(6):1457–1463.
   PubMed Web of Science ®Google Scholar
• Za K, Kn S, Wt K, et al. Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date. Drug Des Devel Ther. 2018 Aug;12:2539–2552.
   PubMed Web of Science ®Google Scholar
• Sheth KN, Kimberly WT, Elm JJ, et al. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit Care. 2014 Aug;21(1):43–51.
   PubMed Web of Science ®Google Scholar
• Kimberly WT, Battey TWK, Pham L, et al. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014 Apr;20(2):193–201.
   PubMed Web of Science ®Google Scholar
• Sheth KN, Kimberly WT, Elm JJ, et al. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke. 2014 Jan;45(1):281–283.
   PubMed Web of Science ®Google Scholar
• Kimberly WT, Bevers MB, Von Kummer R, et al. Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial. Neurology. 2018 Dec;91(23):e2163–e2169.
   PubMed Web of Science ®Google Scholar
• Lange C, Storkebaum E, de Almodóvar CR, et al. Vascular endothelial growth factor: a neurovascular target in neurological diseases. Nat Rev Neurol. 2016 Jul;12(8):439–454.
   PubMed Web of Science ®Google Scholar
• Shim JW, Madsen JR. VEGF signaling in neurological disorders. Int J Mol Sci. 2018 Jan;19.
   Web of Science ®Google Scholar
• Chodobski A, Chung I, Koźniewska E, et al. Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury. Neuroscience. 2003;122(4):853–867.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Fukai N, Nagashijma G, et al. Very early expression of vascular endothelial growth factor in brain oedema tissue associated with brain contusion. Acta Neurochir Suppl. 2003;86:277–279.
   PubMedGoogle Scholar
• Argaw AT, Gurfein BT, Zhang Y, et al. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA. 2009 Feb;106(6):1977–1982.
   PubMed Web of Science ®Google Scholar
• Murakami T, Felinski EA, Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem. 2009 Jul;284(31):21036–21046.
   PubMed Web of Science ®Google Scholar
• Salehi A, Zhang JH, Obenaus A. Response of the cerebral vasculature following traumatic brain injury. J Cereb Blood Flow Metab. 2017 Jul;37(7):2320–2339.
   PubMed Web of Science ®Google Scholar
• Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest. 2000 Oct;106(7):829–838.
   PubMed Web of Science ®Google Scholar
• van Bruggen N, Thibodeaux H, Palmer JT, et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest. 1999 Dec;104(11):1613–1620.
   PubMed Web of Science ®Google Scholar
• Kim MM, Umemura Y, Leung D. Bevacizumab and glioblastoma: past, present, and future directions. Cancer J. 2018;24(4):180–186.
   PubMed Web of Science ®Google Scholar
• Svensson B, Peters M, König H-G, et al. Vascular endothelial growth factor protects cultured rat hippocampal neurons against hypoxic injury via an antiexcitotoxic, caspase-independent mechanism. J Cereb Blood Flow Metab. 2002 Oct;22(10):1170–1175.
   PubMed Web of Science ®Google Scholar
• Greenberg DA, Jin K. Vascular endothelial growth factors (VEGFs) and stroke. Cell Mol Life Sci. 2013 May;70(10):1753–1761.
   PubMed Web of Science ®Google Scholar
• Thau-Zuchman O, Shohami E, Alexandrovich AG, et al. Vascular endothelial growth factor increases neurogenesis after traumatic brain injury. J Cereb Blood Flow Metab. 2010 May;30(5):1008–1016.
   PubMed Web of Science ®Google Scholar
• Tado M, Mori T, Fukushima M, et al. Increased expression of vascular endothelial growth factor attenuates contusion necrosis without influencing contusion edema after traumatic brain injury in rats. J Neurotrauma. 2014 Apr;31(7):691–698.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct;27(28):4733–4740.
   PubMed Web of Science ®Google Scholar
• Tn K, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009 Feb;27(5):740–745.
   PubMed Web of Science ®Google Scholar
• Field KM, Simes J, Nowak AK, et al. CABARET/COGNO investigators, Rosenthal MA. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol. 2015 Nov;17(11):1504–1513.
   PubMed Web of Science ®Google Scholar
• Taal W, Oosterkamp HM, Walenkamp AME, et al. van den Bent MJ. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014 Aug;15(9):943–953.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb;370(8):699–708.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb;370(8):709–722.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Schäfer N, Steinbach JP, et al. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol. 2016 May;34(14):1611–1619.
   PubMed Web of Science ®Google Scholar
• Lombardi G, Pambuku A, Bellu L, et al. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2017 Mar;111:94–102.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Mulholland P, Neyns B, et al. van den Bent M. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep;31(26):3212–3218.
   PubMed Web of Science ®Google Scholar
• Wick W, Vk P, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010 Mar;28(7):1168–1174.
   PubMed Web of Science ®Google Scholar
• Slevin M, Krupinski J, Slowik A, et al. Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke. 2000 Aug;31(8):1863–1870.
   PubMed Web of Science ®Google Scholar
• Mellergård P, Sjögren F, Hillman J. Release of VEGF and FGF in the extracellular space following severe subarachnoidal haemorrhage or traumatic head injury in humans. Br J Neurosurg. 2010 Jun;24(3):261–267.
   PubMed Web of Science ®Google Scholar
• Pikula A, Beiser AS, Chen TC, et al. Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: Framingham Study. Stroke. 2013 Oct;44(10):2768–2775.
   PubMed Web of Science ®Google Scholar
• Dimitrov DS. Therapeutic proteins. Methods Mol Biol. 2012;899:1–26.
   PubMedGoogle Scholar
• Shahror RA, Linares GR, Wang Y, et al. Transplantation of mesenchymal stem cells overexpressing fibroblast growth factor 21 facilitates cognitive recovery and enhances neurogenesis in a mouse model of traumatic brain injury. J Neurotrauma. 2020 Jan;37(1):14–26.
   PubMed Web of Science ®Google Scholar
• Chen J, Hu J, Liu H, et al. FGF21 Protects the Blood-Brain Barrier by Upregulating PPARγ via FGFR1/β-klotho after Traumatic Brain Injury. J Neurotrauma. 2018 Sep;35(17):2091–2103.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang X, Hu J, et al. FGF20 protected against BBB disruption after traumatic brain injury by upregulating junction protein expression and inhibiting the inflammatory response. Front Pharmacol. 2021;11:590669.
   PubMed Web of Science ®Google Scholar
• Deng S, Jin P, Sherchan P, et al. Recombinant CCL17-dependent CCR4 activation alleviates neuroinflammation and neuronal apoptosis through the PI3K/AKT/Foxo1 signaling pathway after ICH in mice. J Neuroinflammation. 2021 Mar;18(1):62.
   PubMed Web of Science ®Google Scholar
• Deng S, Sherchan P, Jin P, et al. Recombinant CCL17 enhances hematoma resolution and activation of ccr4/erk/nrf2/cd163 signaling pathway after intracerebral hemorrhage in mice. Neurotherapeutics. 2020;17(4):1940–1953.
   PubMed Web of Science ®Google Scholar
• Mauceri D, Buchthal B, Hemstedt TJ, et al. Nasally delivered VEGFD mimetics mitigate stroke-induced dendrite loss and brain damage. Proc Natl Acad Sci USA. 2020 Apr;117(15):8616–8623.
   PubMed Web of Science ®Google Scholar
• Yahya EB, Alqadhi AM. Recent trends in cancer therapy: A review on the current state of gene delivery. Life Sci. 2021 Mar;269:119087.
   PubMed Web of Science ®Google Scholar
• Ferrari G, Thrasher AJ, Aiuti A. Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet. 2021;22(4):216–234.
   PubMed Web of Science ®Google Scholar
• Matharu N, Ahituv N. Modulating gene regulation to treat genetic disorders. Nat Rev Drug Discov. 2020 Oct;19(11):757–775.
   PubMed Web of Science ®Google Scholar
• Ghaemi A, Bagheri E, Abnous K, et al. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy. Life Sci. 2021 Feb;267:118969.
   PubMed Web of Science ®Google Scholar
• Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021 Feb;6(1):53.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans–immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990 Aug;323(9):570–578.
   PubMed Web of Science ®Google Scholar
• Ginn SL, Amaya AK, Alexander IE, et al. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018 Apr;20(5):e3015.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004 Jan;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet. 2013 Aug;14(8):535–548.
   PubMed Web of Science ®Google Scholar
• Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000 Feb;403(6772):901–906.
   PubMed Web of Science ®Google Scholar
• Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019 Jan;47(D1):D155–D162.
   PubMed Web of Science ®Google Scholar
• Mueller C, Berry JD, McKenna-Yasek DM, et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N Engl J Med. 2020 Jul;383(2):151–158. DOI:https://doi.org/10.1056/NEJMoa2005056.
   PubMed Web of Science ®Google Scholar
• Täubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021 Jan;42(2):178–188.
   PubMed Web of Science ®Google Scholar
• Esrick EB, Lehmann LE, Biffi A, et al. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2021 Jan;384(3):205–215. DOI:https://doi.org/10.1056/NEJMoa2029392.
   PubMed Web of Science ®Google Scholar
• Eyileten C, Sharif L, Wicik Z, et al. The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke. Mol Neurobiol. 2021 Jan;58(1):329–347.
   PubMed Web of Science ®Google Scholar
• Raikwar SP, Thangavel R, Ahmed ME, et al. Real-Time Noninvasive Bioluminescence, Ultrasound and Photoacoustic Imaging in NFκB-RE-Luc Transgenic Mice Reveal Glia Maturation Factor-Mediated Immediate and Sustained Spatio-Temporal Activation of NFκB Signaling Post-Traumatic Brain Injury in a Gender-Specific Manner. Cell Mol. Neurobiol. 2020 Aug;41(8):1687–1706. https://doi.org/10.1007/s10571-020-00937-9
   PubMed Web of Science ®Google Scholar
• Guedes VA, Devoto C, Leete J, et al. Extracellular vesicle proteins and micrornas as biomarkers for traumatic brain injury. Front Neurol. 2020 Jul;11:663.
   PubMed Web of Science ®Google Scholar
• Pan J, Qu M, Li Y, et al. MicroRNA-126-3p/-5p Overexpression Attenuates Blood-Brain Barrier Disruption in a Mouse Model of Middle Cerebral Artery Occlusion. Stroke. 2020;51(2):619–627.
   PubMed Web of Science ®Google Scholar
• Sonoda T, Matsuzaki J, Yamamoto Y, et al. Serum MicroRNA-Based Risk Prediction for Stroke. Stroke. 2019 Apr;50(6):1510–1518.
   PubMed Web of Science ®Google Scholar
• Shang Y, Dai S, Chen X, et al. MicroRNA-93 regulates the neurological function, cerebral edema and neuronal apoptosis of rats with intracerebral hemorrhage through TLR4/NF-κB signaling pathway. Cell Cycle. 2019 Nov;18(22):3160–3176.
   PubMed Web of Science ®Google Scholar
• Ma Q, Dasgupta C, Li Y, et al. MicroRNA-210 Suppresses Junction Proteins and Disrupts Blood-Brain Barrier Integrity in Neonatal Rat Hypoxic-Ischemic Brain Injury. Int J Mol Sci. 2017 Jun;18.
   Web of Science ®Google Scholar
• Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008 Aug;15(2):272–284.
   PubMed Web of Science ®Google Scholar
• Harris TA, Yamakuchi M, Ferlito M, et al. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA. 2008 Feb;105(5):1516–1521.
   PubMed Web of Science ®Google Scholar
• Xing F, Liu Y, Dong R, et al. miR-374 improves cerebral ischemia reperfusion injury by targeting Wnt5a. Exp Anim. 2021 Feb;70(1):126–136.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang M-D, Xia Y-P, et al. MicroRNA-130a regulates cerebral ischemia-induced blood-brain barrier permeability by targeting Homeobox A5. FASEB J. 2018 Jan;32(2):935–944.
   PubMed Web of Science ®Google Scholar
• Khanna S, Rink C, Ghoorkhanian R, et al. Loss of miR-29b following acute ischemic stroke contributes to neural cell death and infarct size. J Cereb Blood Flow Metab. 2013 Aug;33(8):1197–1206.
   PubMed Web of Science ®Google Scholar
• Long G, Wang F, Li H, et al. Circulating miR-30a, miR-126 and let-7b as biomarker for ischemic stroke in humans. BMC Neurol. 2013 Nov;13(1):178.
   PubMed Web of Science ®Google Scholar
• Gao X, Xiong Y, Li Q, et al. Extracellular vesicle-mediated transfer of miR-21-5p from mesenchymal stromal cells to neurons alleviates early brain injury to improve cognitive function via the PTEN/Akt pathway after subarachnoid hemorrhage. Cell Death Dis. 2020 May;11(5):363.
   PubMed Web of Science ®Google Scholar
• Yao X, Wang Y, Zhang D. microRNA-21 Confers Neuroprotection Against Cerebral Ischemia-Reperfusion Injury and Alleviates Blood-Brain Barrier Disruption in Rats via the MAPK Signaling Pathway. J Mol Neurosci. 2018 May;65(1):43–53.
   PubMed Web of Science ®Google Scholar
• Harraz MM, Eacker SM, Wang X, et al. MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proc Natl Acad Sci USA. 2012 Nov;109(46):18962–18967.
   PubMed Web of Science ®Google Scholar
• Xin H, Liu Z, Buller B, et al. MiR-17-92 enriched exosomes derived from multipotent mesenchymal stromal cells enhance axon-myelin remodeling and motor electrophysiological recovery after stroke. J Cereb Blood Flow Metab. 2020 Aug;271678X20950489.
   Web of Science ®Google Scholar
• Han J, Yang S, Hao X, et al. Extracellular Vesicle-Derived microRNA-410 From Mesenchymal Stem Cells Protects Against Neonatal Hypoxia-Ischemia Brain Damage Through an HDAC1-Dependent EGR2/Bcl2 Axis. Front Cell Dev Biol. 2020;8:579236.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li Y, Chen L, et al. HucMSCs-Derived miR-206-Knockdown Exosomes Contribute to Neuroprotection in Subarachnoid Hemorrhage Induced Early Brain Injury by Targeting BDNF. Neuroscience. 2019 Oct;417:11–23.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang J, Zhang Y, et al. Overexpression of long noncoding RNA Malat1 ameliorates traumatic brain injury induced brain edema by inhibiting AQP4 and the NF-κB/IL-6 pathway. J Cell Biochem. 2019 Jun;120(10):17584–17592.
   PubMed Web of Science ®Google Scholar
• Patel NA, Moss LD, Lee J-Y, et al. Long noncoding RNA MALAT1 in exosomes drives regenerative function and modulates inflammation-linked networks following traumatic brain injury. J Neuroinflammation. 2018 Jul;15(1):204.
   PubMed Web of Science ®Google Scholar
• Lai N, Wu D, Liang T, et al. Systemic exosomal miR-193b-3p delivery attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage in mice. J Neuroinflammation. 2020 Feb;17(1):74.
   PubMed Web of Science ®Google Scholar
• Zhang S, Hu Z-W, Luo H-Y, et al. AAV/BBB-Mediated Gene Transfer of CHIP Attenuates Brain Injury Following Experimental Intracerebral Hemorrhage. Transl Stroke Res. 2020;11(2):296–309.
   PubMed Web of Science ®Google Scholar
• Ni H-Y, Song Y-X, Lin Y-H, et al. Dissociating nNOS (Neuronal NO Synthase)-CAPON (Carboxy-Terminal Postsynaptic Density-95/Discs Large/Zona Occludens-1 Ligand of nNOS) Interaction Promotes Functional Recovery After Stroke via Enhanced Structural Neuroplasticity. Stroke. 2019;50(3):728–737.
   PubMed Web of Science ®Google Scholar
• Li F, Yang B, Li T, et al. HSPB8 over-expression prevents disruption of blood-brain barrier by promoting autophagic flux after cerebral ischemia/reperfusion injury. J Neurochem. 2019;148(1):97–113.
   PubMed Web of Science ®Google Scholar
• Cabral-Miranda F, Nicoloso-Simões E, Adão-Novaes J, et al. rAAV8-733-Mediated Gene Transfer of CHIP/Stub-1 Prevents Hippocampal Neuronal Death in Experimental Brain Ischemia. Mol Ther. 2017 Feb;25(2):392–400.
   PubMed Web of Science ®Google Scholar
• Qu J, Zhao H, Li Q, et al. MST1 Suppression Reduces Early Brain Injury by Inhibiting the NF-κB/MMP-9 Pathway after Subarachnoid Hemorrhage in Mice. Behav Neurol. 2018 Jun;2018:6470957.
   PubMed Web of Science ®Google Scholar
• Guo H, Yin A, Ma Y, et al. Astroglial N-myc downstream-regulated gene 2 protects the brain from cerebral edema induced by stroke. Glia. 2021 Feb;69:281–295.
   PubMed Web of Science ®Google Scholar
• Degeorge ML, Marlowe D, Werner E, et al. Combining glial cell line-derived neurotrophic factor gene delivery (AdGDNF) with L-arginine decreases contusion size but not behavioral deficits after traumatic brain injury. Brain Res. 2011 Jul;1403:45–56.
   PubMed Web of Science ®Google Scholar
• Shirley JL, de Jong YP, Terhorst C, et al. Immune responses to viral gene therapy vectors. Mol Ther. 2020 Mar;28(3):709–722.
   PubMed Web of Science ®Google Scholar
• Murlidharan G, Crowther A, Reardon RA, et al. Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain. JCI Insight. 2016 Sep;1(14):e88034.
   PubMed Web of Science ®Google Scholar
• Bryant DH, Bashir A, Sinai S, et al. Deep diversification of an AAV capsid protein by machine learning. Nat Biotechnol. 2021 Feb;39(6):691–696.
   PubMed Web of Science ®Google Scholar
• Fakhiri J, Grimm D. Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses. Mol Ther. 2021 Apr. DOI:https://doi.org/10.1016/j.ymthe.2021.04.005
   Google Scholar
• Chatterjee D, Marmion DJ, McBride JL, et al. Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9. Gene Ther. 2021 Mar. DOI:https://doi.org/10.1038/s41434-021-00244-y
   Google Scholar
• Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: A clinical reality. Neuron. 2019 Mar;101(5):839–862.
   PubMed Web of Science ®Google Scholar
• Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014 Nov;346(6213):1258096.
   PubMed Web of Science ®Google Scholar
• Cohen J. CRISPR, the revolutionary genetic ‘scissors,’ honored by Chemistry Nobel. Science. 2020 Oct.
   Google Scholar
• Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020 Feb;368(6489):367.
   PubMed Web of Science ®Google Scholar
• Lu Y, Xue J, Deng T, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020 Apr;26(5):732–740.
   PubMed Web of Science ®Google Scholar
• Doench JG, Fusi N, Sullender M, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016 Feb;34(2):184–191.
   PubMed Web of Science ®Google Scholar
• Ran FA, Hsu PD, Lin C-Y, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013 Sep;154(6):1380–1389.
   PubMed Web of Science ®Google Scholar
• Kleinstiver BP, Pattanayak V, Prew MS, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016 Jan;529(7587):490–495.
   PubMed Web of Science ®Google Scholar
• Hou Z, Zhang Y, Propson NE, et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci USA. 2013 Sep;110(39):15644–15649.
   PubMed Web of Science ®Google Scholar
• De Bellis M, Pisani F, Mola MG, et al. Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport. Glia. 2017 Feb;65:790–803.
   PubMed Web of Science ®Google Scholar
• Palazzo C, Buccoliero C, Mola MG, et al. AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding. Acta Neuropathol Commun. 2019 Apr;7(1):51.
   PubMed Web of Science ®Google Scholar
• Guo D, Liu H, Gao G, et al. Generation of an Abcc8 heterozygous mutation human embryonic stem cell line using CRISPR/Cas9. Stem Cell Res. 2016 Nov;17(3):670–672.
   PubMed Web of Science ®Google Scholar
• Guo D, Liu H, Gao G, et al. Generation of an Abcc8 homozygous mutation human embryonic stem cell line using CRISPR/Cas9. Stem Cell Res. 2016 Nov;17(3):640–642.
   PubMed Web of Science ®Google Scholar